Study population
Eligible subjects were currently aged 1 to 24 years old, were post or
currently receiving treatment for a malignancy, and had undergone
evaluation for IO by MRI of the abdomen, heart, and/or pituitary gland.
The decision to screen for IO was at the discretion of the treating
oncologist and which MRI to complete was based on patient-level factors
and clinical judgement. Since 2015, all patients seen in our cancer
survivorship clinic are screened for IO with a serum ferritin level and
referred to IO Clinic for confirmed values > 1000. To
establish the cohort, all patients with a primary oncologic diagnosis
that were seen at CHLA between January 1, 2007 and December 31, 2019
were identified using diagnostic and procedural billing code data from
inpatient and clinic visits.
Subsequently
this list was cross referenced with our clinical database to identify
patients with a diagnosis of cancer who had at least 1 MRI completed for
IO. Patients were included regardless of disease status or treatment
type.